GlassScriptPhysician profile
Steven R Mohnssen
NPI 1568467280
$3,221.29
in general payments reported to CMS, 2019-2025
37 companies · $628 in 2025
The $628 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $495 · 2021: $541 · 2022: $347 · 2023: $479 · 2024: $458 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,034.01 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Harmony Biosciences LLC | $250.54 | 2020-2025 | Wakix |
| Grifols USA, LLC | $227.37 | 2019-2025 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $186.45 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $160.02 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.88 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $112.51 | 2022-2025 | Dupixent |
| Philips North America LLC | $85.60 | 2019-2025 | Vest Therapy Und |
| Avadel Cns Pharmaceuticals, LLC | $77.15 | 2023-2024 | Lumryz |
| Axsome Therapeutics, INC. | $72.38 | 2023-2025 | Sunosi |
| Genentech USA, INC. | $64.82 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $60.67 | 2019-2020 | |
| Mylan Specialty L.P. | $58.09 | 2019-2024 | Yupelri |
| Electromed, INC. | $57.53 | 2024-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $53.65 | 2020-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $52.05 | 2021-2023 | Acthar |
| Amgen INC. | $49.77 | 2021-2024 | Tezspire |
| Genzyme Corporation | $49.54 | 2020-2021 | |
| United Therapeutics Corporation | $36.54 | 2019-2025 | Orenitram |
| Gilead Sciences, INC. | $36.38 | 2022-2023 | Veklury |
| Allergan, INC. | $35.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.20 | 2025 | Glassia |
| Pharming Healthcare, INC. | $28.94 | 2023 | Ruconest |
| Liquidia Technologies, INC. | $25.42 | 2025 | Yutrepia |
| Movair INC | $24.82 | 2025 | Luisa |
| Insmed, INC. | $23.37 | 2023 | Arikayce |
| Advanced Respiratory, INC | $21.35 | 2021 | |
| Mallinckrodt Enterprises LLC | $20.77 | 2019 | |
| Circassia INC. | $20.77 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.08 | 2023 | Soliris |
| Actelion Pharmaceuticals US, INC. | $18.64 | 2019 | |
| Ge Healthcare | $18.12 | 2020 | |
| 3b Medical, INC. | $17.57 | 2025 | Luna |
| Novartis Pharmaceuticals Corporation | $16.04 | 2024 | |
| La Jolla Pharmaceutical Company | $13.62 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.18 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Mohnssen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.